Swelling Losses Haven't Held Back Gains for Ocular Therapeutix (NASDAQ:OCUL) Shareholders Since They're up 302% Over 1 Year

Simply Wall StNov 17 07:54 ET

Scotiabank Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $22

Moomoo NewsNov 15 08:35 ET · Ratings

Ocular Therapeutix (OCUL) Gets a Buy From Scotiabank

TipRanksNov 15 07:46 ET · Ratings

H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $15

Moomoo NewsNov 15 07:33 ET · Ratings

Ocular Therapeutix Is Maintained at Buy by HC Wainwright & Co.

Dow JonesNov 15 07:11 ET · Ratings

BofA Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $18

Moomoo NewsNov 15 05:34 ET · Ratings